Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Declines By 18.9%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 30,900 shares, a decrease of 18.9% from the November 15th total of 38,100 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 1,160,000 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Bio-Path in a research note on Tuesday, December 10th. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors own 5.74% of the company’s stock.

Bio-Path Price Performance

Shares of NASDAQ BPTH traded down $0.04 during midday trading on Friday, reaching $0.66. 44,957 shares of the company traded hands, compared to its average volume of 1,059,295. The stock has a 50-day moving average price of $0.90 and a 200 day moving average price of $1.34. Bio-Path has a 52 week low of $0.59 and a 52 week high of $12.00.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.